HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Intellia Therapeutics
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- ACTIVE_NOT_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 80
- sponsor
- Intellia Therapeutics
- conditions
- Hereditary Angioedema
- interventions
- BIOLOGICAL: NTLA-2002; BIOLOGICAL: Normal Saline IV Administration
- start date
- 2025-01-15
- start date type
- ACTUAL
- primary completion date
- 2026-02-10
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT06634420
- Published
- Oct 9, 2024
- Updated
- Oct 8, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT06634420
- Categories
- Hereditary Angioedema
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials